INCY

Over the past six months, Incyte's stock has experienced fluctuations, closing at $115.30 on October 2, 2026, down 10.50% over 30 days but up 33.64% over 12 months. Its 52-week high was $132.60 on July 28, 2026, and its 52-week low was $82.82 on October 13, 2025. Recent events include the FDA approval of Atebrioz on September 25, 2026. Analysts have a consensus rating of 'Moderate Buy' with an average price target of $127.70, though RBC Capital maintained a 'Sector Perform' rating and raised its price target to $114 on October 5, 2026, while Wall Street Zen lowered Incyte's rating to 'Hold' on October 10, 2026. Incyte is scheduled to release its fiscal Q3 2026 results on October 29, 2026, with analysts anticipating a loss of $3.87 per share. In the past three months, insiders have sold $6,361,428.00 worth of company stock with no purchases.